文献速递白血病MDS 与骨髓增殖性肿瘤

序贯诱导小鼠模型揭示Npm1突变导致Dnmt3a突变克隆性造血恶性转化

Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.
PubMed 文献 · Leukemia · 2019-01-28

研究建立可独立调控Dnmt3a与Npm1突变的小鼠模型,发现Dnmt3a突变模拟克隆性造血(CH),随后诱导Npm1突变使CH进展为骨髓增殖性疾病(MPD),且两突变间隔越长MPD更具侵袭性;移植后MPD均进展为急性髓系白血病(AML),伴HSC/MPP减少及髓系限制性祖细胞增多,后者可在三级受体小鼠中传播AML。

要点

  • Dnmt3a突变可扩增造血干细胞及多能祖细胞(HSC/MPP),模拟克隆性造血。
  • 在Dnmt3a突变CH之后诱导Npm1突变,可致疾病进展为骨髓增殖性疾病(MPD)。
  • MPD移植后均进展为AML,伴HSC/MPP减少和髓系限制性祖细胞增多。

核心结论

  • Npm1突变驱动Dnmt3a突变克隆性造血向AML演变,且CH潜伏期越长疾病进展速度越快。

研究设计与样本

  • 研究建立可独立调控DNA甲基转移酶3A(Dnmt3a)与核磷蛋白1(Npm1)突变的小鼠模型,两种突变分别见于人类CH与AML。

主要发现

  • Dnmt3a突变扩增造血干细胞及多能祖细胞(HSC/MPP),模拟CH。
  • 在Dnmt3a突变CH形成后诱导Npm1突变,导致进展为骨髓增殖性疾病(MPD),两突变间隔越长观察到的MPD更具侵袭性。
  • 移植后MPD均进展为急性髓系白血病(AML),伴HSC/MPP减少及髓系限制性祖细胞增多,后者在三级受体小鼠中传播AML。
  • CH向MPD进展伴随选择激活Ras/Raf/MAPK信号通路的突变。
  • 向AML进展以额外的致癌信号突变(Ptpn11、Pik3r1、Flt3)和/或表观遗传调控因子突变(Hdac1、Idh1、Arid1a)为特征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clonal hematopoiesis (CH) is a common aging-associated condition with increased risk of hematologic malignancy. Knowledge of the mechanisms driving evolution from CH to overt malignancy has been hampered by a lack of in vivo models that orthogonally activate mutant alleles. Here, we develop independently regulatable mutations in DNA methyltransferase 3A (Dnmt3a) and nucleophosmin 1 (Npm1), observed in human CH and AML, respectively. We find Dnmt3a mutation expands hematopoietic stem and multipotent progenitor cells (HSC/MPPs), modeling CH. Induction of mutant Npm1 after development of Dnmt3a-mutant CH causes progression to myeloproliferative disorder (MPD), and more aggressive MPD is observed with longer latency between mutations. MPDs uniformly progress to acute myeloid leukemia (AML) following transplant, accompanied by a decrease in HSC/MPPs and an increase in myeloid-restricted progenitors, the latter of which propagate AML in tertiary recipient mice. At a molecular level, progression of CH to MPD is accompanied by selection for mutations activating Ras/Raf/MAPK signaling. Progression to AML is characterized by additional oncogenic signaling mutations (Ptpn11, Pik3r1, Flt3) and/or mutations in epigenetic regulators (Hdac1, Idh1, Arid1a). Together, our study demonstrates that Npm1 mutation drives evolution of Dnmt3a-mutant CH to AML and rate of disease progression is accelerated with longer latency of CH.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Loberg MA, Bell RK, Goodwin LO, et al. Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis. Leukemia. 2019. PMID: 30692594. doi:10.1038/s41375-018-0368-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。